1 / 9

Africa Pharma Conference 4-5 June 2019, Johannesburg, South Africa

Explore strategies and collaborations for sustainable local production in the public health sector. Understand the importance of regulatory systems, skilled workforce, financing, and market intelligence. Enhance quality assurance to benefit public health and economic growth.

ctiffany
Download Presentation

Africa Pharma Conference 4-5 June 2019, Johannesburg, South Africa

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Jicui DONG (MS, PhD, MBA) Programme Manager (Local Production & Access to Health Commodities) Regulatory Systems Strengthening Regulation of Medicines and Other Health Technologies Access to Medicines, Vaccines and Pharmaceuticals • Africa Pharma Conference • 4-5 June 2019, Johannesburg, South Africa

  2. Local production in the public health context • “The term ‘Local Production’ can be defined in various ways. For the purposes of this statement, ‘local’ refers to the geographical location, i.e. occurring in the country or region, and ‘production’ – in regard to pharmaceuticals for example – refers to all activities along the pharmaceutical manufacturing value chain. Within the context of the public health agenda, promoting local production requires a holistic approach that considers policy coherence, regulatory systems strengthening, access to finance for sustainable production, a careful assessment of the business case, development of skilled human resources, access to technology for production and needs-based innovation, creation of investment incentives and other factors, to enable manufacturers to comply with international quality standards, be competitive and engage in sustainable manufacturing.” – Extracted from the “Interagency Statement on Promoting Local Production of Medicines and Other Health Technologies”

  3. Promoting sustainable quality local production is a cross-cutting endeavour and needs government commitment and policy coherence HEALTH • Different sectors need to work in concert to enable the business environment TRADE INDUSTRY Sustainable Quality Local Production … FINANCE LABOUR EDUCATION

  4. Other key elements for sustainable quality local production Regulatory system Skilled workforce (HR) Capital and Financing Materials & equip (e.g. API, spare parts) Infrastructure (e.g. power, water) Markets (e.g. economies of scale) Foreign direct investment … Market intelligence

  5. Quality assured products are key to achieve public health and economic benefits • Lack of quality assurance puts health at risk • Ineffective treatments • Drug resistance (e.g. AMR) • Adverse events • Lack of quality assurance puts business viability and sustainability at risk • No access to national and international procurement tenders • Financial loss due to product recall • Less attractive to partners and investors • Loss in confidence and trust • PUBLIC HEALTH PERSPECTIVE • BUSINESS PERSPECTIVE

  6. NRA and Industry have a concurrent role to ensure quality • Efficient and transparent regulatory system • Regional and international quality assurance standards • Regulatory convergence and harmonization • Strong partnership with the medical product industry • Build quality into the product • Quality-by-design principles • Product selection • Build quality into the system • GMP in the design of the facility • QMS is a leading factor in GMP non-compliance • Strong partnership with the NRA • NATIONAL REGULATORY AUTHORITY (NRA) • MEDICAL PRODUCT INDUSTRY

  7. WHO supports Member States in strengthening local production with assured quality, safety and efficacy • Setting strategies • Conducting holistic situational analyses • Support in developing and implementing national strategies and roadmaps • Support in strategic selection of products • Tool for risk-based selection of medicines for local production with assured quality • Technical support and capacity building in collaboration with other WHO technical units and external partners • Holistic training workshop • Compliance with quality assurance standards • Nurturing strategic partnerships

  8. Interagency Statement on Promoting Local Production of Medicines and Other Health Technologies • WHA Technical Briefing on Promoting Local Production of Medicines and Other Health Technologies: Official Launch of the Interagency Statement

  9. Thank you Jicui DONG (MS, PhD, MBA) Programme Manager (Local Production & Access to Health Commodities) Regulatory Systems Strengthening Regulation of Medicines and Other Health Technologies Access to Medicines, Vaccines and Pharmaceuticals

More Related